Focus group study now published in BMJ Open
A new study is the first to examine the application of behavioural science in getting underused therapies for Parkinson’s Disease to the patients who need them most.
Alpharmaxim in the press
With many organisations beginning to invest in behavioural science, we’ve been shouting in the press about the benefits for pharma companies.
Ten ways that internal communications can boost your business
Employee engagement, brand alignment, sharing expertise to solve problems: these are all things that internal communications can achieve.
It’s time for behavioural science to take centre stage in health communications
Progress brings new challenges, and help is needed. It might be time for behavioural science to play a bigger part than ever before.
Why Plain Language Summaries are vital in rare disease communications
Plain language summaries can translate complex science for different audiences. But what are they, and how do they improve awareness?
What can COVID-19 campaigns tell us about increasing vaccine uptake?
We examine what lessons we can take from the COVID-19 vaccine campaigns, and how behavioural science insights may help to drive vaccine uptake.
Transforming the rare disease landscape
Over the coming months, we’ll be looking at how new, tailored approaches to communications could help transform the rare disease landscape.
World Alzheimer’s Month 2023
In recognition of World Alzheimer’s Month, we created an animation to explore how Alzheimer’s disease affects patients and their families.
Understanding vaccine hesitancy through the lens of behavioural science
In this latest animation, we explore how a behavioural science-driven approach can help us to better understand the reasons behind vaccine hesitancy.
World Parkinson’s Day 2023
For World Parkinson’s Day 2023, Alpharmaxim created an animation to highlight some of the Parkinson’s symptoms to look out for.
